Compared with other ADCs such as trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) which both target HER2-positive breast tumors (68), SG’s targeting of TROP-2-expressed across multiple breast cancer subtypes including TNBC and HR+ breast cancer, broadens the therapeutic applicability. Here, TACSTD2 is linked to breast neoplasm.